Recurrence of high-risk bladder cancer: A population-based analysis

Cancer

Volumn 119, Issue 17, 2013, Pages 3219-3227

  Chamie, Karim ^a   Litwin, Mark S ^a,b,c   Bassett, Jeffrey C ^a   Daskivich, Timothy J ^a   Lai, Julie ^b   Hanley, Jan M ^b   Konety, Badrinath R ^d   Saigal, Christopher S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RAND CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

bladder cancer mortality; progression; quality of healthcare; recurrence; urinary bladder neoplasms

Indexed keywords

AGED; ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CAUCASIAN; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MORBIDITY; MULTIVARIATE ANALYSIS; NEGRO; PRIORITY JOURNAL; RECURRENT CANCER; REGRESSION ANALYSIS; SEX DIFFERENCE; SOCIOECONOMICS; TUMOR INVASION;

BLADDER CANCER MORTALITY; PROGRESSION; QUALITY OF HEALTHCARE; RECURRENCE; URINARY BLADDER NEOPLASMS;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; RISK FACTORS; SEER PROGRAM; SEX FACTORS; SURVIVAL RATE; TIME FACTORS; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84882701927     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28147     Document Type: Article

References (35)

1. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-036845.pdf.
2. Fedeli U, Fedewa SA, Ward EM,. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011; 185: 72-78.
3. Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS,; Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results -Medicare analysis. Cancer. 2009; 115: 988-996.
4. Herr HW, Dotan Z, Donat SM, Bajorin DF,. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007; 177: 437-443.
5. Madeb R, Golijanin D, Noyes K, et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009; 115: 2660-2670.
6. Huang GJ, Hamilton AS, Lo M, Stein JP, Penson DF,. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol. 2008; 180: 520-524.
7. Chamie K, Saigal CS, Lai J, et al. Urologic Diseases in America Project. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011; 117: 5392-5401.
8. Chamie K, Saigal CS, Lai J, et al. Urologic Diseases in America Project. Quality of care in patients with bladder cancer: a case report? Cancer. 2012; 118: 1412-1421.
9. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (8 suppl): IV-3 to IV-18.
10. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL,. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40 (8 suppl): IV-19 to IV-25.
11. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
13. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
14. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S,. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007; 100: 33-36.
15. Morris DS, Weizer AZ, Ye Z, Dunn RL, Montie JE, Hollenbeck BK,. Understanding bladder cancer death: tumor biology versus physician practice. Cancer. 2009; 115: 1011-1020.
16. Joudi FN, Smith BJ, O'Donnell MA, Konety BR,. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006; 175: 1634-1639.
17. Breyer BN, Whitson JM, Carroll PR, Konety BR,. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010; 28: 510-514.
18. Chamie K, Hu B, Devere White RW, Ellison LM,. Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians? BJU Int. 2008; 182: 284-290.
19. Hollenbeck BK, Miller DC, Taub D, et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology. 2004; 64: 292-297.
20. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983; 130: 1083-1086.
21. Jakse G, Loidl W, Seeber G, Hofstadter F,. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol. 1987; 137: 39-43.
22. Abel PD, Hall RR, Williams G,. Should pT1 transitional cell cancers of the bladder still be classified as superficial? Br J Urol. 1988; 62: 235-239.
23. Pauwels RP, Schapers RF, Smeets AW, Debruyne FM, Geraedts JP,. Grading in superficial bladder cancer. (1). Morphological criteria. Br J Urol. 1988; 61: 129-134.
24. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993; 85: 53-59.
25. Holmäng S, Hedelin H, Anderström C, Johansson SL,. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995; 153: 1823-1826.
26. Herr HW,. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol. 1997; 80: 762-765.
27. Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson SL,. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol. 1997; 157: 800-803.
28. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodríguez J,. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000; 164 (3 pt 1): 680-684.
29. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 465-466.
30. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute. http://seer.cancer. gov/csr/1975-2002/, based on November 2004 SEER data submission, posted to the SEER Web site 2005.
31. Federal Interagency Forum on Aging-Related Statistics. Older Americans Update 2006: Key Indicators of Well-Being. Washington, DC: US Government Printing Office. May 2006.
32. Miller DC, Murtagh DS, Suh RS, Knapp PM, Dunn RL, Montie JE,. Establishment of a urological surgery quality collaborative. J Urol. 2010; 184: 2485-2490.
33. Miller DC, Murtagh DS, Suh RS, et al. Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer. J Urol. 2011; 186: 844-849.
34. Burks FN, Liu AB, Suh RS, et al. Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. J Urol. 2012; 188: 2108-2113.
35. Hollenbeck BK, Taub DA, Miller DC, Dunn RL, Montie JE, Wei JT,. The regionalization of radical cystectomy to specific medical centers. J Urol. 2005; 174 (4 pt 1): 1385-1389.